Please login to the form below

Not currently logged in
Email:
Password:

Smartphone monitoring shows its worth in Roche MS trial

The tool uses smartphone sensors to measure neurological tests

Roche

Remote monitoring of multiple sclerosis patients in trials using a smartphone app is not only feasible, but performs as well as specialist assessments in the clinic, according to a new study.

The latest results from the FLOODLIGHT clinical trial programme show that additional, real-world data using smartphone or smartwatch technology given to patients treated with Roche’s MS therapy Ocrevus (ocrelizumab), which was launched in March, can be a valuable addition to in-clinic measures.

The Android-based app uses smartphone sensors (the accelerometer, gyroscope and magnetometer) to measure both active neurological tests - in which the patient is asked to perform tasks such as daily hand motor function, gait and static balance tests, weekly cognitive tests, and patient-reported outcomes - as well as passive monitoring of metrics on gait and mobility, to provide objective measures of disease progression.

Interim results have been presented at the ECTRIMS-ACTRIMS conference in Paris, and show that the results of the remote patient monitoring matched with the findings of periodic in-clinic tests pretty closely, with some advantages.

For instance, a measurement of hand/arm function using a smartphone-based pinching test may detect impairment in patients whose disease has not yet progressed to the stage where they test positive on a widely-used clinical measure called the nine-hole peg test (9-HPT). Similarly, another assessment - of turning speed - also matched clinical assessments and according to the researchers could spot impairment earlier.

The data “support FLOODLIGHT as a potential complement to in-clinic testing to provide a more complete and consistent picture of a patient’s disease progression”, said Roche, adding that the tool “enables a continuous stream of precise, real-world MS disease progression data to be collected and analysed using dedicated algorithms and machine learning”.

MS isn’t the first disease in which Roche had used this app-based monitoring technology. The company has also put an app for Parkinson’s disease through its paces within a phase I trial of drug candidate Prothena-partnered RG7935 which got underway in 2015. That programme advanced to phase II earlier this year.

Meanwhile, Novartis has also been looking at the use of smartphone-collected data in MS in its elevateMS study, which got underway in August and is focused on understanding the daily challenges for MS patients and trying to develop new real-time measures that can be used to help determine treatment effectiveness.

Article by
Phil Taylor

3rd November 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Porterhouse Insights
Porterhouse Medical launch strategic insight and research consultancy
Porterhouse Insight will offer solutions to pharmaceutical clients...
Where is health behaviour change heading?
Cures rely on patient adherence to succeed, and health behaviour change in any non-compliant patient is essential, this post explores where health behaviour change is heading....
Pharma email marketing: Your top 12 tips
Used correctly, email can be one of the most effective and cost-efficient channels for a pharma company to use. To help you get the most from it, we've rounded up...

Infographics